Nicholas Scott Heaton

Nicholas Scott Heaton

Assistant Professor of Molecular Genetics and Microbiology

Appointments and Affiliations

  • Assistant Professor of Molecular Genetics and Microbiology
  • Member of the Duke Cancer Institute
  • Member of the Duke Human Vaccine Institute

Contact Information

  • Email Address: nicholas.heaton@duke.edu

Education

  • Ph.D. The University of Chicago, 2012

Courses Taught

  • MGM 593: Research Independent Study
  • MGM 701: Foundations of Molecular Genetics and Microbiology

In the News

Representative Publications

  • Froggatt, HM; Burke, KN; Chaparian, RR; Miranda, HA; Zhu, X; Chambers, BS; Heaton, NS, Influenza A virus segments five and six can harbor artificial introns allowing expanded coding capacity., Plos Pathog, vol 17 no. 9 (2021) [10.1371/journal.ppat.1009951] [abs].
  • Drayman, N; DeMarco, JK; Jones, KA; Azizi, S-A; Froggatt, HM; Tan, K; Maltseva, NI; Chen, S; Nicolaescu, V; Dvorkin, S; Furlong, K; Kathayat, RS; Firpo, MR; Mastrodomenico, V; Bruce, EA; Schmidt, MM; Jedrzejczak, R; Muñoz-Alía, MÁ; Schuster, B; Nair, V; Han, K-Y; O'Brien, A; Tomatsidou, A; Meyer, B; Vignuzzi, M; Missiakas, D; Botten, JW; Brooke, CB; Lee, H; Baker, SC; Mounce, BC; Heaton, NS; Severson, WE; Palmer, KE; Dickinson, BC; Joachimiak, A; Randall, G; Tay, S, Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2., Science, vol 373 no. 6557 (2021), pp. 931-936 [10.1126/science.abg5827] [abs].
  • Froggatt, HM; Harding, AT; Chaparian, RR; Heaton, NS, ETV7 limits antiviral gene expression and control of influenza viruses., Sci Signal, vol 14 no. 691 (2021) [10.1126/scisignal.abe1194] [abs].
  • Trimarco, JD; Heaton, BE; Chaparian, RR; Burke, KN; Binder, RA; Gray, GC; Smith, CM; Menachery, VD; Heaton, NS, TMEM41B is a host factor required for the replication of diverse coronaviruses including SARS-CoV-2., Plos Pathog, vol 17 no. 5 (2021) [10.1371/journal.ppat.1009599] [abs].
  • Luo, Z; Girton, AW; Heaton, BE; Heaton, NS, Engineered influenza virions reveal the contributions of non-hemagglutinin structural proteins to vaccine mediated protection., J Virol (2021) [10.1128/JVI.02021-20] [abs].